Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nova Mentis Life Science Corp C.NOVA

Alternate Symbol(s):  NMLSF

Healthcare Biotechnology
Nova Mentis Life Science Corp. is a Canadian biotechnology company. The Company is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. The Company has orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS). Its focus is to diagnose and treat debilitating chronic... see more

Recent & Breaking News (CSE:NOVA)

Nova Mentis Announces Change of Directors

Newsfile February 26, 2024

Nova Mentis Applauds Government Decision to Create Rare Disease Advisory Group

Newsfile November 3, 2023

Nova Mentis Announces Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome

Newsfile August 30, 2023

Nova Mentis (CSE:NOVA) enters mRNA AI diagnostics business

Jonathon Brown April 26, 2023

Nova Mentis to Enter mRNA AI Diagnostics Business

Newsfile April 26, 2023

Nova Mentis Begins Recruitment in First-of-its-Kind Health Canada Psilocybin Trial

Newsfile April 18, 2023

Nova Mentis Receives Institutional Review Board Approval to Commence Psilocybin Clinical Trial

Newsfile April 11, 2023

Nova Mentis Provides Corporate Update and 2023 Outlook

Newsfile April 5, 2023

Novel Therapeutic Solutions are Needed as Autism Rates Increase

Newsfile March 29, 2023

Autism rates are increasing in children, we need this next-level therapeutic solution

Jonathon Brown March 29, 2023

Nova Mentis (CSE:NOVA) approved to begin psilocybin clinical trial

Jonathon Brown February 14, 2023

Nova Mentis Granted Health Canada Section 56 Exemption to Begin Psilocybin Clinical Trial

Newsfile February 14, 2023

Nova Mentis (CSE:NOVA) appoints Derek Ivany as Executive Chairman

Shoran Devi January 18, 2023

Nova Mentis Appoints Derek Ivany as Executive Chairman

Newsfile January 18, 2023

Nova Mentis (CSE:NOVA) receives Health Canada approval for psilocybin clinical trial

Trevor Abes  December 22, 2022

IIROC Trade Resumption - NOVA

Canada NewsWire December 22, 2022

Nova Mentis Receives Health Canada Approval for First-Of-Its-Kind Psilocybin Clinical Trial

Newsfile December 22, 2022

IIROC Trading Halt - NOVA

Canada NewsWire December 22, 2022

Nova Mentis' Psilocybin Preclinical Study Published in International Science Journal

Newsfile December 8, 2022

Nova (CSE:NOVA) submits Phase II A psilocybin clinical trial application to Health Canada

Azuka Onwuka November 30, 2022